Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H20ClNO7 |
| Molecular Weight | 421.828 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](CC1=CC=C2OC(OC2=C1)(C(O)=O)C(O)=O)NC[C@H](O)C3=CC(Cl)=CC=C3
InChI
InChIKey=JEDJMKTVUPSHFW-ABAIWWIYSA-N
InChI=1S/C20H20ClNO7/c1-11(22-10-15(23)13-3-2-4-14(21)9-13)7-12-5-6-16-17(8-12)29-20(28-16,18(24)25)19(26)27/h2-6,8-9,11,15,22-23H,7,10H2,1H3,(H,24,25)(H,26,27)/t11-,15+/m1/s1
| Molecular Formula | C20H20ClNO7 |
| Molecular Weight | 421.828 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/21170122 | https://www.ncbi.nlm.nih.gov/pubmed/11311069 | https://www.ncbi.nlm.nih.gov/pubmed/26988163
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/21170122 | https://www.ncbi.nlm.nih.gov/pubmed/11311069 | https://www.ncbi.nlm.nih.gov/pubmed/26988163
CL-316243 is a selective and highly specific β3-adrenoceptor agonist. CL 316243 possesses anti-obesity and anti-diabetic effects due to increasing brown adipose tissue thermogenesis and metabolic rate, and consequently may be useful for treating obesity as well as non-insulin-dependent diabetes mellitus in obese persons, without causing excessive side effects.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL246 |
220.0 nM [EC50] | ||
Target ID: CHEMBL210 |
262.0 µM [EC50] | ||
Target ID: CHEMBL213 |
111.0 µM [EC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Sample Use Guides
The daily dose for rats was 1 mg/ kg body weight for 4 weeks
Route of Administration:
Oral
Effect of CL (CL-316243) alone or in combination with ADA, PTX or WT on PI(3,4,5)P3 production were studied using rat epididymal adipocytes. [32P]orthophosphate-labeled adipocytes that were treated or not treated with ADA (2 U/ml, 10 min) or PTX (1 μg/ml, 60 min) were incubated for 1 min with or without CL (1 μM). In addition, [32P]orthophosphate-labeled adipocytes treated with or without WT (3 μM, 1 min) were incubated for 1 min with or without CL or INS (0.7 μM). Furthermore, adipocytes treated or not treated with ADA or PTX were incubated for 10 min with or without CL. The radioactivity of PI(3,4,5)P3 (PIP3) that were separated by TLC and the accumulation of cAMP in adipocytes were determined.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:22:03 UTC 2023
by
admin
on
Sat Dec 16 10:22:03 UTC 2023
|
| Record UNII |
52H8DB0TKX
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
52H8DB0TKX
Created by
admin on Sat Dec 16 10:22:04 UTC 2023 , Edited by admin on Sat Dec 16 10:22:04 UTC 2023
|
PRIMARY | |||
|
5486546
Created by
admin on Sat Dec 16 10:22:04 UTC 2023 , Edited by admin on Sat Dec 16 10:22:04 UTC 2023
|
PRIMARY | |||
|
183720-02-7
Created by
admin on Sat Dec 16 10:22:04 UTC 2023 , Edited by admin on Sat Dec 16 10:22:04 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
